BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19775298)

  • 1. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.
    De Filippi P; Zecca M; Lisini D; Rosti V; Cagioni C; Carlo-Stella C; Radi O; Veggiotti P; Mastronuzzi A; Acquaviva A; D'Ambrosio A; Locatelli F; Danesino C
    Br J Haematol; 2009 Dec; 147(5):706-9. PubMed ID: 19775298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
    De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
    Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation.
    Matsuda K; Nakazawa Y; Sakashita K; Shiohara M; Yamauchi K; Koike K
    Haematologica; 2007 Nov; 92(11):1576-8. PubMed ID: 18024411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K; Matsuda K
    Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
    Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
    Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular biology of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2010 Jul; 51(7):526-31. PubMed ID: 20693772
    [No Abstract]   [Full Text] [Related]  

  • 7. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y; Muramatsu H; Makishima H; Prince C; Jankowska AM; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
    Matsuda K; Sakashita K; Taira C; Tanaka-Yanagisawa M; Yanagisawa R; Shiohara M; Kanegane H; Hasegawa D; Kawasaki K; Endo M; Yajima S; Sasaki S; Kato K; Koike K; Kikuchi A; Ogawa A; Watanabe A; Sotomatsu M; Nonoyama S; Koike K
    Br J Haematol; 2010 Feb; 148(4):593-9. PubMed ID: 19874312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutional trisomy 8p11.21-q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia.
    Ripperger T; Tauscher M; Praulich I; Pabst B; Teigler-Schlegel A; Yeoh A; Göhring G; Schlegelberger B; Flotho C; Niemeyer CM; Steinemann D
    Br J Haematol; 2011 Oct; 155(2):209-17. PubMed ID: 21848520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
    Pérez B; Mechinaud F; Galambrun C; Ben Romdhane N; Isidor B; Philip N; Derain-Court J; Cassinat B; Lachenaud J; Kaltenbach S; Salmon A; Désirée C; Pereira S; Menot ML; Royer N; Fenneteau O; Baruchel A; Chomienne C; Verloes A; Cavé H
    J Med Genet; 2010 Oct; 47(10):686-91. PubMed ID: 20543203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
    Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
    Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)].
    Koike K; Matsuda K
    Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092
    [No Abstract]   [Full Text] [Related]  

  • 17. Juvenile myelomonocytic leukaemia: a case series.
    Azma RZ; Zarina AL; Hamidah A; Jamal R; Sharifah NA; Ainoon O; Hamidah NH
    Malays J Pathol; 2009 Dec; 31(2):121-8. PubMed ID: 20514855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous remission of juvenile myelomonocytic leukemia with NRAS mutation.
    Alsultan A; Khalifah M; Alrabiaah AA
    Pediatr Hematol Oncol; 2012 Oct; 29(7):624-6. PubMed ID: 22857389
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.
    de Vries AC; Stam RW; Kratz CP; Zenker M; Niemeyer CM; van den Heuvel-Eibrink MM;
    Haematologica; 2007 Nov; 92(11):1574-5. PubMed ID: 18024410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.